Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Holdings Boosted by Seven Eight Capital LP

Seven Eight Capital LP grew its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 688.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 75,971 shares of the company’s stock after purchasing an additional 66,332 shares during the quarter. Seven Eight Capital LP owned 0.09% of Syndax Pharmaceuticals worth $1,560,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in Syndax Pharmaceuticals by 13.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 577,022 shares of the company’s stock worth $12,469,000 after acquiring an additional 70,555 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Syndax Pharmaceuticals by 28.0% in the 4th quarter. Principal Financial Group Inc. now owns 55,194 shares of the company’s stock worth $1,193,000 after purchasing an additional 12,074 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in Syndax Pharmaceuticals by 158.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after purchasing an additional 1,496 shares during the last quarter. UBS Group AG lifted its stake in Syndax Pharmaceuticals by 151.7% during the fourth quarter. UBS Group AG now owns 290,801 shares of the company’s stock valued at $6,284,000 after purchasing an additional 175,244 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in Syndax Pharmaceuticals during the fourth quarter worth approximately $3,101,000.

Syndax Pharmaceuticals Stock Up 3.5 %

Syndax Pharmaceuticals stock opened at $18.63 on Friday. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.22 and a 12 month high of $25.34. The stock has a market cap of $1.59 billion, a P/E ratio of -5.79 and a beta of 0.91. The company’s fifty day simple moving average is $20.82 and its 200-day simple moving average is $21.21.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The firm had revenue of $3.50 million during the quarter. Syndax Pharmaceuticals’s quarterly revenue was up 3499999990.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) EPS. On average, equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

SNDX has been the subject of a number of recent research reports. Scotiabank downgraded Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 14th. Citigroup upped their target price on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Barclays lifted their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. reduced their price objective on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, HC Wainwright lifted their target price on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).